Olivia de la Calle‐Jiménez

Olivia de la Calle‐Jiménez

Auto-generated profile, based on publicly available information

Olivia de la Calle‐Jiménez

Immunopathology and Viral Reservoir Unit, National Center of Microbiology Instituto de Salud Carlos III, Majadahonda Madrid Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2025 in Journal of Medical Virology
Verified
Journal Article
Open access
OCOlivia de la Calle‐Jiménez
Olivia de la Calle‐Jiménez
GCGuiomar Casado‐Fernández
Guiomar Casado‐Fernández
IAInés Armenteros‐Yeguas
Inés Armenteros‐Yeguas
LLLuis Lemus‐Aguilar
Luis Lemus‐Aguilar
BBBegoña Baza
Begoña Baza
MCMayte Coiras
Mayte Coiras
In August 2024, the World Health Organization declared mpox infection a Public Health Emergency of International Concern for second time since 2022 and recommended vaccinating all people at‐risk, such as people with HIV‐1 (PWH) and prophylaxis pre‐exposition (PrEP) users. We recruited PWH and PrEP users who received one or two doses of subcutaneous Imvanex® or Jynneos® and compared specific T‐cell immunity with participants who passed mpox natural infection or were Nonexposed to mpox. CD4 + T cells from people who had mpox showed the highest capacity to produce IL‐2 (1.8‐fold, p = 0.0328), as well as IFNγ (2.5‐fold, p = 0.0247), and IL‐4 (1.8‐fold, p = 0.0373) from naïve CD4 + T cells, in response to MHC‐II‐restricted mpox‐related peptides, compared to vaccinated participants. CD8 + T cells from individuals who had mpox also showed the highest capacity to produce IFN (1.6‐fold, p = 0.0321) and TNF (2.1‐fold, p = 0.0084) against MHC‐I‐restricted peptides. Therefore, the most potent and robust T‐cell responses were developed after mpox infection, while they were barely detectable after vaccination. These results support the need to explore booster doses or improved vaccines to enhance cellular immunity in at‐risk populations. More studies are needed to evaluate the capacity of mpox vaccines to confer long‐term protection.

8 November 2025 in Journal of Medical Virology
Verified
Journal Article
Open access
GCGuiomar Casado‐Fernández
Guiomar Casado‐Fernández
OCOlivia de la Calle‐Jiménez
Olivia de la Calle‐Jiménez
IAInés Armenteros
Inés Armenteros
LALuis Lemus Aguilar
Luis Lemus Aguilar
DFDaniel Fuertes
Daniel Fuertes
MCMayte Coiras
Mayte Coiras
In May 2022, a large outbreak of monkeypox virus (MPXV) occurred in several non‐endemic regions worldwide. Another outbreak in 2024 raised global concerns, particularly for immunocompromised individuals like people with HIV (PWH). Since the latent HIV‐1 reservoir remains a major barrier to a cure, we investigated how past mpox infection affected reservoir dynamics in this population. PWH who had mpox at an average of 9 months before sampling showed a significantly smaller HIV‐1 reservoir than MPXV‐unexposed PWH. This reduction was accompanied by enhanced antigen‐driven proviral reactivation in CD4+ T cells, especially central memory cells (TCM), and increased expression of T‐cell activation and proliferation markers like CD32 and Ki67. Mpox also induced sustained immune stress, as reflected by a prolonged decrease in CD4+ T naïve (TN) cells, increased expression of immune senescence and exhaustion markers like PD‐1, LAG‐3, and CD57, as well as metabolic dysfunction in CD4+ TN and TCM cells, which showed impaired glucose uptake and reduced proliferative capacity. These findings suggest that MPXV‐induced immune activation leads to long‐lasting changes in T‐cell homeostasis and reprograms the HIV‐1 reservoir, which may have implications for monitoring immune competence and vaccine responses in this population. Understanding the interplay between HIV‐1/MPXV co‐infection, T‐cell dynamics, and HIV‐1 reservoir modulation provides novel insights into how controlled proviral reactivation may inform the design of cure‐oriented strategies.